Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 18/20 | 0.79 |
| ▸ | CDK2 | P24941 | 2/20 | 0.69 |
| ▸ | MARK3 | P27448 | 2/20 | 0.69 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.69 |
| ▸ | BRSK2 | Q8IWQ3 | 2/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.69 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.69 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.67 |
| ▸ | ULK1 | O75385 | 2/20 | 0.66 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386373 | 0.91 | TBK1 (0.75) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL3385790 | 0.89 | TBK1 (0.75) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL3385788 | 0.89 | TBK1 (0.74) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL13431940 | 0.88 | TBK1 (1.00) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL13431935 | 0.86 | TBK1 (0.84) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL13431954 | 0.84 | TBK1 (1.00) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL13431942 | 0.84 | TBK1 (0.78) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL13431981 | 0.84 | TBK1 (0.77) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL13431977 | 0.83 | TBK1 (0.73) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL13431848 | 0.83 | TBK1 (0.76) | TBK1CDK2MARK3IKBKEBRSK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056524-A1 | Compound | NR3C2, NR3C1, NR2E3 | TBK1 2898/4885CDK2 393/4885MARK3 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.